Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyHodgkin LymphomaIndolent LymphomasTransplantationDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C83.7C84.4C88.0-C91.0-C91.1-MeSHLymphoma, FollicularLymphoma, Mantle-CellLymphoma, T-Cell, PeripheralPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)MOSU(1/2/60), B-NHL, C1 (PID2105) -|- C2 (PID2106) -|- C3+ (PID2107)ODRO(0.2/0.5/2/10), FL °I-IIIa, C1 (PID2897) -|- ODRO80, C2 (PID2898) -|- C3-4 (PID2899) -|- ODRO160, maint. 2 (PID2900) -|- maint. 4 (PID2901)ChemotherapyChemo-substanceCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneEtoposideFludarabineHuman albumin 20%MelphalanMethylprednisoloneMosunetuzumabNaCl 0.9%OdronextamabRituximabChemo-substanceCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneEtoposideFludarabineHuman albumin 20%MelphalanMethylprednisoloneMosunetuzumabNaCl 0.9%OdronextamabRituximabChemo-substanceCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneEtoposideFludarabineHuman albumin 20%MelphalanMethylprednisoloneMosunetuzumabNaCl 0.9%OdronextamabRituximabChemo-substanceCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneEtoposideFludarabineHuman albumin 20%MelphalanMethylprednisoloneMosunetuzumabNaCl 0.9%OdronextamabRituximabNo. Substances12346 RadiotherapySupportive therapySupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chloridePrednisoloneNo. Substances235678Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRefractory diseaseRelapse therapyseveral possibleTherapy phaseInductionMaintenanceSalvageTherapy intentioncurativedisease controlpalliativeRisksAnemia Hb below 8g/dlCardiotoxicityCytokine Release SyndromeDiarrheaDyspneaEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHyperglycemiaHypertensionHypocalcemiaHypokalemiaHypophosphatemiaHypotensionIncrease AminotransferasesInfectionsLymphopeniaNeuropathyNeutropeniaPneumoniaRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorBannerji RBudde LEDavies AKirschey SLiu E Tessoulin BVelasquez WSDiseaseB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieB-Non-Hodgkin-Lymphom/Hodgkin LymphomFollikuläres Lymphom °I-IIIa, Zweitlinie nach CD20 Antikörper, ECOG 0-1Lymphom, Rezidiv oder refraktär, mit mindestens einer anthrazyklinhaltigen VortherapieNon-Hodgkin-Lymphom / Hodgkin Lymphomrezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2rezidiviertes oder refraktäres B-NHL, mindestens zwei vorherige systemische BehandlungenOriginCancer Research UK Centre, University of Southampton, UK, SABRINA StudieCity of Hope National Medical Center, Duarte, CADepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzNantes Medical University, Nantes, FranceRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA, ELM-1 trialSection of Lymphoma, M.D. Anderson Cancer Center, Houston, TXUniversity of Texas M.D. Anderson Cancer Center, HoustonProtocols in Revision 14 protocols foundProtocols under revision.DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346 V1.0)ESHAP - Etoposide 40 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 375, Non-Hodgkin Lymphoma. (PID2348 V1.0)Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471 V2.0)Mosunetuzumab (1/2/60), B-Non-Hodgkin Lymphoma, cycle 1 (PID2105 V1.0)Mosunetuzumab 30, B-Non-Hodgkin Lymphoma, cycle 3+ (PID2107 V1.0)Mosunetuzumab 60, B-Non-Hodgkin lymphoma, cycle 2 (PID2106 V1.0)Odronextamab (0.2/0.5/2/10), follicular Lymphoma °I-IIIa, cycle 1 (PID2897 V1.0)Odronextamab 160, follicular Lymphoma °I-IIIa, maintenance 2 weeks (PID2900 V1.0)Odronextamab 160, follicular Lymphoma °I-IIIa, maintenance 4 weeks (PID2901 V1.0)Odronextamab 80, follicular Lymphoma ° I-IIIa, cycle 3-4 (PID2899 V1.0)Odronextamab 80, follicular Lymphoma °I-IIIa, cycle 2 (PID2898 V1.0)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345 V1.0)Rituximab 1400, single dose subcutaneous (PID310 V2.0)
